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Abstract
Progressive supranuclear palsy (PSP) is a 4R-tauopathy predominated by subcortical pathology in neurons, astrocytes, and 
oligodendroglia associated with various clinical phenotypes. In the present international study, we addressed the question of 
whether or not sequential distribution patterns can be recognized for PSP pathology. We evaluated heat maps and distribution 
patterns of neuronal, astroglial, and oligodendroglial tau pathologies and their combinations in different clinical subtypes 
of PSP in postmortem brains. We used conditional probability and logistic regression to model the sequential distribution 
of tau pathologies across different brain regions. Tau pathology uniformly predominates in the neurons of the pallido-nigro-
luysian axis in different clinical subtypes. However, clinical subtypes are distinguished not only by total tau load but rather 
cell-type (neuronal versus glial) specific vulnerability patterns of brain regions suggesting distinct dynamics or circuit-
specific segregation of propagation of tau pathologies. For Richardson syndrome (n = 81) we recognize six sequential steps 
of involvement of brain regions by the combination of cellular tau pathologies. This is translated to six stages for the practi-
cal neuropathological diagnosis by the evaluation of the subthalamic nucleus, globus pallidus, striatum, cerebellum with 
dentate nucleus, and frontal and occipital cortices. This system can be applied to further clinical subtypes by emphasizing 
whether they show caudal (cerebellum/dentate nucleus) or rostral (cortical) predominant, or both types of pattern. Defining 
cell-specific stages of tau pathology helps to identify preclinical or early-stage cases for the better understanding of early 
pathogenic events, has implications for understanding the clinical subtype-specific dynamics of disease-propagation, and 
informs tau-neuroimaging on distribution patterns.
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Introduction
Progressive supranuclear palsy (PSP) is a four-repeat (4R) 
tauopathy that belongs to the group of frontotemporal lobar 
degeneration (FTLD-tau) disorders [34]. The neuropatho-
logical diagnosis of PSP is based on the presence of neu-
rofibrillary tangles and threads in subcortical nuclei together 
with the presence of tufted astrocytes [5, 13]. In addition, 
oligodendroglial coiled bodies and diffuse cytoplasmic 
immunoreactivity in neurons can be observed as well [9, 
18]. Following the proposal of typical, atypical, and com-
bined cases of PSP by Lantos [26], Williams et al. provided 
evidence for biochemical and tau pathology load differences 
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between PSP with Parkinsonism (PSP-P) and the classical 
clinical phenotype Richardson syndrome (PSP-RS) [47, 48]. 
Soon thereafter, further clinical phenotypes with PSP-type 
tau pathology were described [6]. In 2017, the Movement 
Disorders Society suggested clinical diagnostic criteria to 
recognize these distinct clinical subtypes as PSP-RS, PSP-
P, PSP with corticobasal syndrome (PSP-CBS), PSP with 
progressive gait freezing (PSP-PGF), PSP with predominant 
ocular motor dysfunction (PSP-OM), with predominant pos-
tural instability (PSP-PI), with predominant frontal presen-
tation (PSP-F), or with predominant speech and language 
disorder (PSP-SL) [14].
Neuropathological studies on smaller cohorts suggest 
differences in the burden of tau pathology between clinical 
subtypes. Williams et al. noted in 2007 that the mean sever-
ity of pathology in all regions of the PSP-RS group (n = 22) 
was higher than in PSP-P (n = 14) and PSP with pure aki-
nesia with gait freezing (currently called PSP-PGF, n = 6), 
and the overall tau load was significantly higher in PSP-RS 
than in PSP-P. Sakae et al. compared PSP-RS (n = 31) cases 
with PSP-F (n = 15) and found increased tau burden only in 
the superior frontal gyrus gray matter and inferior temporal 
gyrus white matter in PSP-F [36]. Tsuboi et al. examined 
cases (n = 5) presenting with PSP-CBS and concluded that 
this is most likely due to either concurrent cortical pathol-
ogy, or to the primary pathology of PSP affecting cortical 
areas that are primarily and commonly affected by cortico-
basal degeneration (CBD), another 4R tauopathy [45]. Ling 
et al. also examined PSP-CBS cases (n = 10) and demon-
strated that the overall severity of tau pathology was the 
same between PSP-CBS and PSP-RS but with a shift of tau 
burden towards the cortical regions [27]. On the other hand, 
the rare PSP-PGF variant showed almost no cortical tau 
pathology, but severe degeneration of the globus pallidus, 
substantia nigra, and subthalamic nucleus, hence called also 
pallido-nigro-luysian degeneration [1].
In addition to the recognition of clinical subtypes, a novel 
concept raises the possibility of propagation of pathologi-
cal tau in PSP as well as other tauopathies [11] providing a 
potential therapeutic target [16, 34]. Indeed, sequential dis-
tribution patterns have been recognized for tau pathologies 
such as neurofibrillary degeneration in Alzheimer’s disease 
(AD) [3], Pick’s disease [15], argyrophilic grain disease 
[35], or astrocytic tau pathologies [24] as well as for other 
proteinopathies such as beta-amyloid, alpha-synuclein or 
TDP-43 (for review see: [19]). Regarding PSP, Williams 
et al. proposed a scoring system of tau pathology allowing 
the recognition of sequential distribution patterns in PSP-RS 
[48]. However, due to the variability of tau cytopathologies 
and clinical phenotypes, a staging system such as that devel-
oped focusing only on neuronal protein depositions exem-
plified by neurofibrillary tangles [3] or Lewy bodies [4] has 
not yet been proposed for PSP. Based on these unresolved 
issues, we set up an international group to collect different 
clinical subtypes with PSP pathology. We compared the dis-
tribution patterns of tau cytopathologies and used heat maps 
and conditional probability matrix to evaluate whether or 
not sequential patterns of tau pathology can be recognized 
and whether the clinical subtypes show distinct distribution 
patterns of tau cytopathologies.
Materials and methods
Case cohort
This study includes 206 individuals in banked collection of 
brains from longitudinally followed subjects at the Center of 
Neurodegenerative Disease Research (CNDR) Brain Bank at 
the University of Pennsylvania, Philadelphia, PA and brain 
banks in Munich, Germany, Barcelona, Spain, London, UK, 
and Rotterdam, The Netherlands (Table 1). Cases for the 
study were selected based on the presence of globose NFTs 
in the subthalamic nucleus, substantia nigra, and globus 
pallidus together with tufted astrocytes in the striatum and 
eventually in the frontal cortex. Cases were grouped follow-
ing PSP-RS, PSP-P, PSP-CBS, PSP-PGF, PSP-OM, PSP-
PI, PSP-F, or PSP-SL using the operationalized Movement 
Disorders Society diagnostic PSP criteria [14], by move-
ment disorders experts (DI, GR) based on the records in the 
patient’s ante mortem clinical files, as described previously 
[31]. Data were obtained from clinical charts and may be 
incomplete and underestimated. In order to minimalize this 
retrospective limitation, we relied on clinically obvious signs 
and symptoms relevant to our analysis, which were com-
monly reported by patient, caregiver and/or documented by 
doctor. Clinical features were considered present if specifi-
cally mentioned in the clinical notes. They were considered 
absent if they were specifically mentioned as absent, or if 
they were not mentioned.
Immunohistochemistry and evaluation of tau 
pathologies
Formalin fixed, paraffin-embedded tissue blocks from the 
investigated cases were evaluated. Immunostaining for tau 
was performed with anti-tau PHF-1 (Ser396/Ser404, 1:2000; 
Gift of Peter Davies) and the AT8 antibody (Ser202/Thr205, 
1:200, Invitrogen/Thermofischer, MN1020, Carlsbad, USA. 
For concomitant proteinopathies, we evaluated these cases 
for Aβ, TDP-43, and alpha-synuclein pathologies as well as 
for vascular lesions [33, 44].
We evaluated neuronal (tangles and diffuse cytoplasmic 
immunoreactivity and threads), astrocytic (tufted astrocytes 
and other morphologies pooled together), and oligoden-
droglial (coiled bodies together with threads in the white 
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matter) tau pathologies using a semiquantitative score (none, 
mild, moderate, severe). The following anatomical regions 
were examined: The middle frontal gyrus, anterior cingulate, 
inferior parietal gyrus, superior and middle temporal gyrus, 
precentral gyrus, and occipital cortex (including the stri-
ate, para- and peristriate regions), hippocampus (pyramidal 
layers and dentate gyrus together), amygdala, the caudate-
putamen, globus pallidus, thalamus and subthalamic nucleus 
(these are in one block), the midbrain tegmentum, substantia 
nigra, locus coeruleus, pontine base, tegmentum, and infe-
rior olives of the medulla oblongata (together represented 
here as medulla oblongata for the conditional probability 
analysis), cerebellar white matter (threads and coiled bod-
ies), and dentate nucleus (neuronal and rarely astroglial 
tau pathology). For the block containing the subthalamic 
nucleus and thalamus, neuronal tau pathology scores are 
provided for the subthalamic nucleus and astroglial and oli-
godendroglial for the thalamus.
Conceptual approach and statistical analysis
Our approach contained three steps: (1) We used the mean of 
the semiquantitative scores total tau pathology in each exam-
ined region to generate heatmaps [15, 22]; (2) we described 
patterns and compared semiquantitative score of cellular tau 
pathologies (neuronal, astroglial, and oligodendroglial) in 
different anatomical regions; followed by (3) comparison 
of different anatomical regions and cellular pathologies to 
calculate conditional probabilities (see below), which region 
and which cellular pathology (i.e., neuronal, astroglial, or 
oligodendroglial) might precede another one. In addition, 
for total tau scores we performed binary logistic regression 
analysis to evaluate the effect of additional pathological vari-
ables and age.
We applied conditional probability analysis as reported 
recently for the evaluation of sequential stages of aging-
related tau astrogliopathy (ARTAG) pathology [24]. 
Accordingly, we compared two regions in all combina-
tions for discordance. This can mean that one region is 
affected (any score) while the other is not (negative). The 
cases included in this study showed clinical symptoms 
and, therefore, were not considered as presymptomatic 
where one could expect that many regions lack tau pathol-
ogy. Therefore, we applied a modified strategy: for the 
dichotomic stratification score 1 represented if one region 
was affected moderately or severely, while score 0 was 
given if a region was not or only mildly affected. The null 
hypothesis was that region A being positive with moder-
ate or severe scores of any or sum of tau pathology while 
region B being negative or showing mild score of any or 
Table 1  Demographic data of 
cases examined in this study
RS Richardson syndrome, P parkinsonism, OM predominant ocular motor dysfunction, PI predominant 
postural instability, F predominant frontal presentation, CBS predominant corticobasal syndrome, SL pre-
dominant speech and language disorder, PGF progressive gait freezing
PSP syn-
drome
Country Sex Total Mean Age SE Mean duration (n) SE
Europe USA Male Female
RS n 27 54 47 34 81 73.20 0.8 6.7 (n = 77) 0.3
% 13% 26.2% 22.8% 16.5% 39.3%
F n 11 14 16 9 25 73.80 2.1 6.1 (n = 25) 0.5
% 5.3% 6.7% 7.7% 4.3% 12.1%
P n 13 7 14 6 20 75.40 1.7 11.8 (n = 20) 1.1
% 6.3% 3.3% 6.7% 2.9% 9.7%
PI n 20 0 15 5 20 74.30 1.4 7.1 (n = 20) 0.5
% 9.7% 0.0% 7.2% 2.4% 9.7%
SL n 6 4 5 5 10 74.50 2.2 7.6 (n = 9) 0.8
% 2.9% 1.9% 2.4% 2.4% 4.8%
CBS n 3 6 5 4 9 73.56 1.8 5.7 (n = 9) 0.8
% 1.4% 2.9% 2.4% 1.9% 4.3%
OM n 4 0 1 3 4 71.75 4.4 5.0 (n = 3) 1.5
% 1.9% 0.0% 0.5% 1.4% 1.9%
PGF n 1 1 1 1 2 77.50 4.5 9.5 (n = 2) 5.5
% 0.5% 0.5% 0.5% 0.5% 1.0%
OTHER n 27 8 17 18 35 75.26 1.3 7.3 (n = 25) 0.9
% 13.1% 3.8% 8.2% 8.7% 16.9%
Total n 112 94 121 85 206 74.02 0.5 7.1 (n = 194) 0.2
% 54.30% 45.6% 58.7% 41.2% 100.0%
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sum of tau pathology and the region A being negative or 
showing mild score of any or sum of tau pathology, and 
region B being positive with moderate or severe scores of 
any or sum of tau pathology is equally likely; thus A and 
B region is affected (i.e., showing accumulation of tau 
pathology) at the same time (i.e., being in the same stage). 
Thus, this reflects whether one region accumulates tau 
pathology earlier than another one. McNemar’s test was 
used to assess the evidence against the null hypothesis. We 
generated a matrix for total tau and for different cellular 
tau types involving various anatomical regions where each 
cell in the matrix corresponds to a conditional probabil-
ity that one region is involved before another one. Condi-
tional probability was calculated using crosstab function 
of SPSS. SPSS Statistics Version 24 was used for statisti-
cal analysis. The conditional probability of region A to 
precede region B or vice versa was calculated as follows:
Region A Region B
Tau pathol-
ogy present 
(moderate/
severe)
Tau pathol-
ogy not 
present or 
only mild
Tau pathology present (moderate/
severe)
W X
% of cases within region A % %
% of cases within region B % Conditional 
probability 
A preced-
ing B
Tau pathology not present or only mild Y Z
% of cases within region A Conditional 
probability 
B preced-
ing A
%
% of cases within region B % %
If the conditional probability for one region was signifi-
cantly higher than for the other region we interpreted that 
that this region was most likely to be affected before the 
other. We interpreted the results analogously to the meas-
urement of observer agreement for categorical data [23, 
25]. If the conditional probability was > 0.80 (and p value 
was < 0.01) we interpreted that that particular region is 
highly likely to precede another region. If the conditional 
probability was 0.61–0.80, then it was interpreted as substan-
tial, 0.41–0.60 as moderate, and 0.21–0.4 as fair and < 0.21 
as poor evidence that the involvement of one region precedes 
the involvement of the other one. If the conditional probabil-
ity was high for both (> 0.80) and the p value was < 0.01, we 
interpreted the results based on the frequencies of involve-
ment of the examined variable in regions.
Binary logistic regression models were additionally used 
to generate odds ratios (OR) and 95% confidence intervals 
(CI), where the presence of tau pathology (any type) in the 
examined anatomical regions were the dependent variables, 
and age, duration of illness and presence of AD-related 
pathology (i.e., amyloid plaques), Braak NFT stage, and 
argyrophilic grain disease (AGD)-related pathology were the 
independent variables. To generate dichotomic values for the 
binary logistic regression we used the sum of the dichotomic 
scores of cellular tau pathology scores dichotomized again 
with the same concept. This means that if the sum of the 
dichotomic scores (0 or 1) of each cellular tau pathology was 
0 or 1 we used the value 0 and if the sum was 2 or 3 we used 
the value 1. In case the OR > 10 with a significant p value 
we interpreted this as high likelihood that two regions are 
affected together. In case OR < 1 we interpreted this as less 
likely that the two regions were affected together; eventually 
meaning they could be affected independently.
Heat maps and pathology patterns were generated for 
PSP-RS, PSP-F, PSP-P, PSP-S, PSP-CBS, and PSP-PI. For 
PSP-PGF (n = 2) and PSP-OM (n = 4) we generated heat-
maps for an overview but did not include these cases in fur-
ther analyses. For detailed statistical evaluation we pooled 
clinical PSP subtypes and additionally we evaluated PSP-RS 
separately as well. We did not include PSP cases where the 
clinical phenotype could not be clearly determined (“other”).
For conditional probability analysis we applied a signifi-
cance level of 0.01 for McNemar’s test and 0.05 for logistic 
regression with multiple independent variables. We chose a 
lower significance level than the traditional 0.05 for McNe-
mar’s test in order to reduce the likelihood of false-positive 
findings. However, for the sake of completeness, we sepa-
rately indicated those comparisons where p value was < 0.05.
In addition, one-way ANOVA and Tukey post hoc tests 
were used to compare age at death and duration of illness in 
different clinical groups. Kruskal–Wallis with Mann–Whit-
ney post hoc tests were used to compare the differences 
between duration of illness in six clinical groups and the 
scores of total tau load and tau cytopathologies in the clini-
cal groups in different anatomical regions. For significant 
results we performed ordinal regression analysis with cor-
rection for presence of AD pathology, age, and duration of 
illness.  Chi2 square test was used to compare the frequencies 
of sexes in clinical groups. For these examinations p < 0.05 
was considered significant.
Results
Demographic summary of cases
Demographic data of 206 cases included in the study are 
summarized in Table 1. The most frequent form is PSP-
RS (n = 81). Age at death was available for all cases, while 
duration of illness was lacking in a few cases due to unclear 
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records on symptom onset. Age at death did not show sig-
nificant differences between groups. Duration of illness 
was significantly longer in cases with PSP-P than those 
with PSP-RS (p = 0.001), PSP-F (p = 0.001), PSP-CBS 
(p = 0.002) or PSP-PI (p = 0.002). There was no difference 
in the distribution of sexes within clinical groups.
Spatial features of cellular tau pathologies 
distinguish PSP subtypes
Anatomical matrix of total tau scores of pooled clinical 
subtypes shows that tau pathology concentrates in sub-
cortical and brainstem nuclei (Fig. 1). There were only a 
few cases with low tau scores in the thalamus/subthalamus 
but with higher scores in the striatum and globus pallidus. 
To highlight differences of anatomical vulnerability pat-
terns between clinical subtypes, we generated heat maps of 
total tau scores (Fig. 2 and online supplemental file Fig. 1. 
for PSP-PGF and PSP-OM). Kruskal–Wallis test with 
Mann–Whitney post hoc test revealed significant differences 
between clinical subtypes in several brain regions (Table 2). 
Following a correction for presence of AD pathology, age, 
and duration illness, total tau load was higher in PSP-RS 
than in PSP-P (globus pallidus) and was less than in PSP-PI 
in neocortical and brainstem regions, furthermore less than 
in PSP-SL and PSP-CBS in neocortical regions. In PSP-
PI total tau load was higher than in PSP-F and PSP-CBS 
in brainstem regions as well as that in PSP-P in brainstem 
regions. Furthermore, PSP-P showed less total tau accumu-
lation in neocortical regions and selected subcortical and 
brainstem nuclei than PSP-CBS and PSP-SL. Finally, PSP-
SL and PSP-CBS showed more total tau load in some neo-
cortical regions than PSP-F (for details see Table 2).
Next, we compared the load of different cellular tau 
pathologies in clinical subtypes. Neuronal tau pathology 
affects mostly brainstem and subcortical nuclei but involve-
ment of the amygdala and hippocampus is also considerable 
in all subtypes (Fig. 3a). Astroglial tau pathology clearly 
predominates in cortical areas and striatum and shows dif-
ferences between clinical subtypes in all cortical areas, 
thalamus/subthalamus and substantia nigra (Fig. 3b). Fur-
thermore, accumulation of oligodendroglial tau pathology 
is characteristic in subcortical nuclei and shows variability 
between subtypes in most of the cortical and subcortical and 
brainstem regions and cerebellum (Fig. 3c). Mann–Whitney 
test reveals significant differences between subtypes in sev-
eral brain regions for each neuronal, astroglial, and oligo-
dendroglial tau pathologies (Table 3). In logistic regression 
models, the duration of illness did not show any effect on 
these differences. Adding the presence of AD type pathol-
ogy (i.e., presence of plaques), AGD, and age showed an 
effect on the results of differences of neuronal tau accumu-
lation in the occipital and premotor cortex, amygdala and 
hippocampus but not in the frontal, parietal, and tempo-
ral cortices. While comparison of each clinical phenotype 
showed differences of at least one tau cytopathology in at 
least one region, major differences were noted in astroglial 
and oligodendroglial tau accumulation between PSP-RS and 
PSP-P, PSP-RS and PSP-PI, PSP-F and PSP-P, PSP-F and 
PSP-PI, PSP-PI and PSP-P, PSP-P and PSP-CBS, PSP-PI 
and PSP-SL and PSP-PI and PSP-CBS (Table 3). Neuronal 
tau accumulation was different mostly between PSP-RS and 
PSP-P, PSP-RS and PSP-PI, PSP-RS and PSP-SL, PSP-PI 
and PSP-F, PSP-P and PSP-PI and PSP-PI and PSP-CBS 
(Table 3). Neuronal loss correlated well with total tau load 
only in subcortical and brainstem regions and not in neocor-
tical areas, likely due to the fact that cortical tau pathology 
was predominated by astroglial tau.
The sum of the three different cellular tau pathologies 
is the highest in the striatum and the thalamus/subthalamic 
nucleus and the frontal, parietal, and motor cortices (exem-
plified by PSP-RS, PSP-P, PSP-F, PSP-PI, see online supple-
mental file, Figs. 2, 3, 4). This is due to the fact that brain-
stem nuclei accumulate less glial tau pathologies or only one 
type, such as oligodendroglial in the globus pallidus, pontine 
base, or cerebellum, and dentate nucleus.
Finally, we evaluated the combined effect of age, dura-
tion of illness, presence of AD-related pathology (plaques), 
Braak NFT stage and presence of AGD pathology on 
regional cellular tau pathologies. AGD pathology was 
found in 78 out 194 cases where diagnostically relevant 
regions were available for examination (40.2%, no differ-
ence between clinical phenotypes according to  Chi2 test). 
Presence of AGD and Braak NFT stage showed signifi-
cantly higher (p = 0.002 and 0.007, respectively) OR values 
for hippocampal neuronal tau pathology (OR 25.03, 95% 
CI 3.11–200.8, and 2.14, 95% CI 1.23–3.72, respectively). 
Neuronal and oligodendroglial tau pathology in the amyg-
dala was significantly associated with the presence of AGD 
pathology (p = 0.0001, OR 10.16, 95% CI 2.8–35.6 and 
p = 0.006, OR 5.4 95% CI 1.6–18.6, respectively). Presence 
of astroglial tau pathology in the amygdala did not associ-
ate with presence of AGD (p = 0.4) or other variables in 
the model. Occipital cytopathologies were not influenced 
by these variables in this model.
In summary, total tau load is in general less in the cortex 
in PSP-P (and PSP-PGF in two cases) and more prominent 
in PSP-SL (Fig. 2). However, tau pathology in PSP shows 
clinical subtype and cell type-specific differences in its ana-
tomical distribution. As general rules, the following were 
observed:
1. Subcortical and brainstem nuclei are most vulnerable for 
neuronal tau accumulation; however, the motor cortex is 
also involved;
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2. Cortical areas and the striatum are characterized by pre-
dominance of astroglial tau pathology;
3. Oligodendroglial tau shows the most variability in clini-
cal subtypes; and finally,
4. It is important to note that the amygdala and hippocam-
pus consistently show tau pathology; however, neuronal 
tau pathology might indicate concomitant primary age-
related tauopathy (PART) or AD or AGD.
Conditional probability analysis for pooled PSP 
cases
We included in sum 165 pooled cases of PSP-RS, PSP-P, 
PSP-F, PSP-SL, PSP, PI, and PSP-CBS for this analysis. Our 
aim with this model was to evaluate whether the accumula-
tion of tau pathology in a certain region precedes another, 
irrespective of the type of cellular tau pathology (online 
supplemental file, Figs. 5, 6). According to this, high or 
substantial evidence exists that involvement of subcortical 
regions precede cortical areas (first towards fronto-parietal 
cortices and then to temporal and finally occipital cortices) 
and dentate nucleus/cerebellar white matter (Fig. 4). This is 
reminiscent of the distribution map presented by Williams 
et al., in 2007, but the recognition of mild involvement of 
the occipital cortex found in our study expands beyond the 
regions shown there [48].
Relation of tau pathological variables in different 
anatomical regions in Richardson syndrome
To predict early vulnerable cellular populations, we were 
next interested to discern which anatomical regions are 
affected when most others are spared any type of tau pathol-
ogy. This analysis (Fig. 5) showed for PSP-RS (n = 81) that 
the subcortical nuclei (striatum, globus pallidus, subtha-
lamic nucleus, and thalamus) and selected brainstem nuclei 
(substantia nigra, locus coeruleus, and medulla oblongata) 
show tau pathology in all cases. If the amount of tau pathol-
ogy is low, then it was always neuronal rather than glial 
tau pathology in these regions. A single case with PSP-RS 
showed small amounts of neuronal tau pathology in the 
subthalamic nucleus, striatum, substantia nigra, and globus 
pallidus together with Lewy body and TDP-43 pathology. 
This observation supports the notion that these regions are 
early vulnerable regions for the development of the PSP-RS 
clinical phenotype. Following the development of a stag-
ing system (see below) we added the proposed stages to the 
cases (Fig. 5).
We provide the detailed table of conditional probabilities 
for PSP-RS cases together with the frequencies of low (0 
and 1) and high (2 and 3) scores for each anatomical region 
and tau cytopathology in the online supplemental file Fig. 7, 
and here summarize the combined interpretation. Since the 
motor cortex was not examined in all cases of RS and the 
conditional probability results were similar as for the frontal 
cortex we show only the results of the frontal cortex.
Figure 6 demonstrates which cellular tau pathology in 
which anatomical region precedes one another with vari-
ous degrees of likelihood. This shows that accumulation 
of neuronal tau pathology in the substantia nigra, midbrain 
tegmentum, locus coeruleus, pontine base, medulla oblon-
gata, globus pallidus and subthalamic nucleus, and thalamus 
precedes any type of tau pathology in neocortical regions. 
Accumulation of neuronal tau in these regions precedes 
accumulation of neuronal tau in the dentate nucleus. Neu-
ronal tau pathology accumulates later in the striatum but pre-
cedes neuronal tau accumulation in the parietal, temporal, 
and occipital cortices. The amygdala and hippocampus show 
accumulation of neuronal pathology earlier than neocortical 
neuronal tau. Amygdala is preceded by the accumulation 
of neuronal tau in the subthalamic nucleus and brainstem 
nuclei and hippocampus is preceded by the substantia nigra 
and locus coeruleus. In the cortex, accumulation of neu-
ronal tau in the frontal cortex precedes that in the parietal 
and occipital cortices. Neuronal tau in the hippocampus and 
amygdala precedes accumulation of tau pathologies in corti-
cal areas except for astroglial tau in the parietal and frontal 
cortices. However, early hippocampal involvement might be 
related to PART or AD pathology.
The striatum is different from other subcortical and brain-
stem nuclei, since here astroglial tau pathology accumulates 
more and earlier than neuronal tau pathology in the striatum 
and this occurs in parallel to the neuronal tau accumula-
tion in other subcortical and brainstem nuclei. Astroglial tau 
pathology in the striatum precedes astroglial tau pathology 
in neocortical areas and thalamus. Importantly, in neocorti-
cal areas, except for the occipital cortex, significant values 
in conditional probability analyses suggest that astroglial 
tau pathology precedes the accumulation of neuronal or 
oligodendroglial tau pathology. Astroglial tau pathology 
accumulates later in the parietal, temporal, and occipital 
cortices, brainstem nuclei, hippocampus, and amygdala than 
in the frontal cortex. Astroglial tau in the occipital lobe and 
Fig. 1  Distribution map of total tau semiquantitative scores (0–3) in 
PSP-Richardson syndrome (PSP-RS), PSP-frontal variant (PSP-F), 
PSP-Parkinsonism (PSP-P), PSP-postural instability (PSP-PI), PSP-
speech-language variant (PSP-SL) and PSP-corticobasal syndrome 
(PSP-CBS). Black boxes indicate that that anatomical region was not 
examined. White box indicates score 0, yellow score 1, orange score 
2, and red score 3 for semiquantitative scoring. Columns indicate ana-
tomical regions, rows indicate individual patients. If more than six 
brain regions were not available the cases are not shown in this figure. 
OC Occipital, TE temporal, PA parietal, FR frontal, MC motor cortex, 
AM amygdala, HI hippocampus, ST striatum, TH thalamus and sub-
thalamic nucleus, GP globus pallidus, TG midbrain tegmentum, SN 
substantia nigra, LC locus coeruleus, PB pontine base, MO medulla 
oblongata, DE/CB dentate nucleus and cerebellar white matter
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midbrain tegmentum precedes the locus coeruleus, medulla 
oblongata or dentate nucleus.
Finally, oligodendroglial tau pathology accumulates in 
the globus pallidus early and prominently and conditional 
probability analyses reveal a similar pattern as seen for the 
accumulation of neuronal tau. Oligodendroglial tau pathol-
ogy in other regions does not seem to be accumulating early 
in the disease. Involvement of the subthalamic nucleus and 
thalamus and the striatum precedes neocortical areas and 
brainstem. Based on conditional probability analyses in the 
cortex the sequence seems to be frontal and parietal to tem-
poral and occipital lobe.
Binary logistic regression was performed with multi-
ple variables (i.e., age, duration, and presence of AD type 
pathology) to evaluate the odds ratios that two compared 
anatomical regions show accumulation of tau pathology 
simultaneously. This analysis confirms that neocortical 
areas are affected only if subcortical and brainstem nuclei 
are also affected (online supplemental file, Fig. 8). Impor-
tantly, it also shows that the involvement of the hippocampus 
and locus coeruleus is independent from the involvement 
of strategic subcortical and brainstem nuclei. On the other 
hand, tau pathology in the amygdala accumulates together 
with neocortical regions.
To summarize
Tau pathology in PSP-RS begins with neuronal tau accu-
mulation in subcortical and brainstem nuclei along with 
early oligodendroglial involvement in the globus pallidus 
and astroglial involvement in the striatum. This is followed 
by astroglial tau accumulation in cortical areas, which pre-
cedes cortical neuronal and oligodendroglial tau accumula-
tion, altogether following a fronto-parietal to temporal to 
occipital sequence.
Discussion
The present study compared different clinical subtypes asso-
ciated with PSP tau pathology and evaluated which cyto-
pathologies in which anatomical regions precede others in 
PSP-RS. We show  the following:
1. Common early vulnerability patterns characterize all 
PSP clinical subtypes jointly, i.e. affecting mainly the 
pallido-nigro-luysian axis;
Fig. 2  Heat mapping of total tau scores in PSP-Richardson syndrome 
(PSP-RS), PSP-frontal variant (PSP-F), PSP-Parkinsonism (PSP-P), 
PSP-postural instability (PSP-PI), PSP-speech-language variant (PSP-
SL) and PSP-corticobasal syndrome (PSP-CBS). The severity of tau 
pathology ranges from white (none) through yellow and orange to red 
(severe). Gray colored cortical regions indicate that the region was 
not evaluated
◂
Table 2  Differences between 
total tau scores of PSP-
Richardson syndrome (RS), 
PSP-frontal variant (F), PSP-
Parkinsonism (P), PSP-postural 
instability (PI), PSP-speech-
language variant (SL), and PSP-
corticobasal syndrome (CBS)
Greater-than signs indicate which clinical phenotype (in the order shown in the left column) shows signifi-
cantly more tau pathology in a specific region after correction for AD pathology, duration of illness, and 
age. Greater-than signs with and asterisk show the significant results in Mann–Whitney test, which were 
not confirmed in the regression model
OC Occipital, TE temporal, PA parietal, FR frontal, MC motor cortex, AM amygdala, HI hippocampus, ST 
striatum, STN/TH subthalamic nucleus and thalamus, GP globus pallidus, TG midbrain tegmentum, SN 
substantia nigra, LC locus coeruleus, PB pontine base, MO medulla oblongata, DE/CB dentate nucleus and 
cerebellar white matter
STN/ TH GP SN ST TG LC PB MO DE/CB AM HI MC FR PA TE OC
RS/F  > 
RS/P  > 
RS/PI  <  <  >  <  <  < *  < 
RS/SL  <  < *  < 
RS/CBS  < 
F/P  > *  > *
PI/F  >  >  > 
F/SL  <  < *
F/CBS  < 
PI/P  >  >  >  >  >  > *  > *
P/SL  <  <  <  < *  < 
P/CBS  <  < 
PI/SL
PI/CBS  >  >  > 
SL/CBS
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2. Tau pathology propagates rostrally to neocortical regions 
and caudally to the cerebellum including the dentate 
nucleus;
3. Neuronal tau accumulation is the first step in the early 
affected pallido–nigro–luysian axis, but in some regions 
astroglial or oligodendroglial tau pathology precedes 
neuronal tau pathology;
4. Significant differences in tau burden, but particularly dif-
ferent tau cytopathologies, distinguish clinical subtypes.
Common early vulnerability but distinct 
propagation patterns in PSP clinical subtypes
We applied different methods to confirm that the pal-
lido–nigro–luysian axis is the early vulnerable region in PSP 
subtypes. This has been described in the original description 
of PSP [43] and emphasized in the diagnostic criteria [13] 
and in a model based on regional tau scores [48]. Impor-
tantly, neuronal tau pathology was observed in the locus 
coeruleus and hippocampus also; however, at least for PSP-
RS, we showed that this was independent from the involve-
ment of strategic subcortical and brainstem nuclei, and 
might represent or overlap with other pathogenic events such 
as AD or PART or, particularly for the hippocampus and 
amygdala, with the presence of AGD, which was frequently 
seen in our cohort (40.2%). On the other hand, observations 
on distinct subregional distribution of tau pathology in the 
hippocampus in PSP suggest that there is an AD/PART-
independent pathogenic process of the involvement of the 
hippocampus [29].
Recently, several neuropathologic studies reported 
incidental or early stage PSP cases, supporting the impor-
tance of the pallido–nigro–luysian axis. Evidente et al. [8] 
reported five cases (6.9% of their cohort) with Gallyas-pos-
itive pathology fulfilling criteria of PSP but lacking clinical 
symptoms. They reported that the mean severity scores of 
Gallyas-positive PSP features were significantly lower in 
subjects with neuropathological incidental PSP than subjects 
with clinical PSP, with the subthalamic nucleus and puta-
men showing the greatest difference [8]. Kovacs et al. [21] 
reported five cases (2.1% in their cohort) with PSP pathology 
in an aging-study (not included in the present study), three 
of them without clinical symptoms but with tau pathology 
involving subcortical areas. Dugger et al. (2014) reported 
four cases (5% of their cohort, three of which were reported 
by Evidente et al. [8]). Three of their cases showed neuronal 
tau in the substantia nigra, two in the subthalamic nucleus 
and globus pallidus with variable involvement of cortical 
areas [7]. A single case showed tufted astrocytes in the cor-
tex but no neuronal tau pathology in subcortical areas [7], 
which did not fulfil neuropathologic criteria of PSP. Nogami 
et al. [30] reported eight cases (2.5% in their consecutive 
autopsy cohort), which they termed preclinical PSP. All 
their cases showed neuronal tau pathology in the substantia 
nigra and either in the globus pallidus (6/8), subthalamic 
nucleus (4/8), putamen (5/8) or dentate nucleus (7/8) [30]. 
A single case contained tufted astrocytes in several regions 
[30]. Yoshida et al. [50] described 29 PSP cases (2.9%) in 
a forensic autopsy cohort, 13 of which showed low amount 
of pathology involving the globus pallidus, subthalamic 
Fig. 3  Graphic representation of semiquantitative scores of different 
cellular tau pathologies (a neuronal, b astroglial, c oligodendroglial) 
in PSP clinical subtypes. To avoid overcrowding of the graphs, three 
subtypes are shown in bars and three with lines. Significant (p < 0.05) 
results of Mann–Whitney test are shown for each comparison in D 
(blue box indicates neuronal, N, red box for astroglial, A, and green 
for oligodendroglial, O). OC Occipital cortex, TE temporal cortex, PA 
parietal cortex, FR frontal cortex, MC motor cortex, AM amygdala, 
HI hippocampus, ST striatum, TH thalamus and subthalamic nucleus, 
GP globus pallidus, TG midbrain tegmentum, SN substantia nigra, 
LC locus coeruleus, PB pontine base, MO medulla oblongata, DE/CB 
dentate nucleus and cerebellar white matter
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Table 3  Differences of cellular tau pathologies in PSP subtypes [PSP-Richardson syndrome (RS), PSP-frontal variant (F), PSP-Parkinsonism 
(P), PSP-postural instability (PI), PSP-speech-language variant (SL), and PSP-corticobasal syndrome (CBS)]
Greater-than signs indicate which clinical phenotype (in the order shown in the left column) shows significantly (Mann–Whitney test, p < 0.05) 
more cellular tau pathology (neuronal compared to neuronal, astroglial compared to astroglial and oligodendroglial compared to oligodendro-
glial) in a specific region. Note that differences of neuronal tau accumulation in the occipital and premotor cortex, amygdala, and hippocampus 
were lost after correction for age, duration of illness, presence of AD, and AGD pathology
OC Occipital, TE temporal, PA parietal, FR frontal, MC motor cortex, AM amygdala, HI hippocampus, ST striatum, STN subthalamic nucleus, 
TH thalamus, GP globus pallidus, TG midbrain tegmentum, SN substantia nigra, LC locus coeruleus, PB pontine base, MO medulla oblongata, 
DE/CB dentate nucleus and cerebellar white matter, Astro astroglia, OligoD oligodendroglia
Clinical subtype Tau/Cell STN/TH GP SN ST TG LC PB MO DE/CB AM HI MC FR PA TE OC
RS/F Neuron  > 
Astro
OligoD  > 
RS/P Neuron  >  >  > 
Astro  >  >  >  >  >  >  >  > 
OligoD  >  >  >  >  >  >  >  >  >  >  > 
RS/PI Neuron  <  <  <  <  <  <  <  <  < 
Astro  >  > 
OligoD  >  >  >  >  >  >  >  >  <  >  >  > 
RS/SL Neuron  <  <  < 
Astro  <  <  < 
OligoD  >  >  > 
RS/CBS Neuron
Astroglia  <  <  < 
OligoD
F/P Neuron  > 
Astro  >  >  >  >  > 
OligoD  >  >  >  >  > 
F/PI Neuron  <  <  <  <  < 
Astro  <  <  < 
OligoD  >  >  >  >  >  >  >  > 
F/SL Neuron  < 
Astro  <  < 
OligoD
F/CBS Neuron
Astro  < 
OligoD  < 
P/PI Neuron  <  <  <  <  <  <  <  < 
Astro  >  <  <  <  <  < 
OligoD
P/SL Neuron  <  < 
Astro  <  <  <  <  <  <  < 
OligoD  <  <  <  < 
P/CBS Neuron
Astro  <  <  <  <  <  < 
OligoD  <  <  <  <  <  <  <  <  <  < 
PI/SL Neuron  >  > 
Astro  <  <  <  <  < 
OligoD  <  < 
PI/CBS Neuron  >  >  >  > 
Astro  <  <  < 
OligoD  <  <  <  <  <  <  <  <  < 
SL/CBS Neuron
Astro
OligoD  <  <  <  < 
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nucleus, substantia nigra, and pontine nucleus. Many of 
them had clinical symptoms in spite of not being diagnosed 
as PSP [50]. Finally, a further case who deceased 2 months 
after the clinical onset showed neuronal degeneration only 
in the subthalamic nucleus and substantia nigra with more 
widespread tau pathology [38]. Importantly, the subthalamic 
nucleus is predominated by neuronal tau pathology, while 
other thalamic nuclei are affected by various cytopathologies 
showing differences between thalamic nuclei [12].
We theorize that from the common initiating sites in PSP 
clinical subtypes tau cytopathologies then propagate in dif-
ferent dynamics and patterns. Interestingly, intrinsic con-
nectivity networks, anchored by the dorsal midbrain, whose 
nodes include the brainstem, basal ganglia, diencephalic, 
cerebellar and cortical regions have been recently estab-
lished [10]. These outline a comprehensive architecture of 
node pairwise connections for this system and show that 
PSP–related connectivity breakdowns emphasize cortico-
subcortical and cortico-brainstem interactions [10]. Several 
studies addressed the issue of distinct anatomical involve-
ments as a basis for clinical variability, however, focusing on 
tau burden or neuronal tau pathology [17, 27, 36, 37, 39, 45]. 
The scoring system developed by Williams et al. considered 
coiled bodies and thread tau pathology as an important fea-
ture [48]. As a novel finding we report here that in addition 
to differences in overall total tau burden, neuronal, astro-
glial, and oligodendroglial tau pathologies involve clinical 
subtypes differently. In particular, neuronal tau differs the 
least, astroglial tau pathology differs mostly in neocortical 
areas, while oligodendroglial also in subcortical regions (see 
Fig. 3). Interestingly, PSP-P, which generally shows a slower 
disease progression than PSP-RS [41], differs mostly by the 
lower degree of glial involvement and particularly of cortical 
regions. This underpins the importance of glial tau pathol-
ogy, which might reflect distinct propagation mechanisms of 
tau or differences in the response to neuronal degeneration 
[20]. The relevance of astroglial tau pathology has been 
discussed in distinguishing PSP and pallido–nigro–luysian 
degeneration [49]. Interestingly, early involvement of astro-
cytes is a feature of CBD [28] and has been also reported in 
brain regions not affected by neuronal tau in Pick’s disease 
[15, 24]. The discrepancy between neuronal and glial tau 
pathology in different PSP is intriguing also in the context 
of divergent patterns of transcriptional associations for neu-
ronal and astroglial tau lesions [2]. Indeed, while neuronal 
tau pathology positively associated with a brain co-expres-
sion network enriched in synaptic and PSP candidate risk 
genes, astroglial tau pathology positively associated with a 
microglial gene-enriched immune network [2]. Finally, these 
observations carry a message for tau neuroimaging since 
the tracers should be able to detect glial tau also if these 
distribution patterns are targeted to be recognized. Impor-
tantly, PSP-PI showed several differences compared to other 
subtypes. As reported in other studies [32], we did not find 
difference in duration of illness for PSP-PI (except when 
compared to PSP-P). Early PSP-PI might resemble PSP-RS 
and accordingly does not show longer disease duration but 
associates with a significant neuropathological burden.
Proposed sequential patterns of tau pathologies 
in Richardson syndrome
We recognize sequential distribution patterns that consider 
the accumulation of different cellular tau pathologies. Based 
on this and on reports on early stage, incidental, or preclini-
cal PSP [7, 8, 30, 50], and as well as on reports on map-
ping of scores of tau pathologies [48], we propose a staging 
schema for PSP-RS. The conditional probability analysis 
used here focuses on the accumulation (dichotomized as no/
mild versus moderate/severe) of any cellular tau pathology. 
Thus, we cannot exclude that single tau cytopathologies are 
Fig. 4  Heatmap showing the 
development of tau pathology 
based on conditional probability 
matrix of total tau pathology 
scores in pooled cases of differ-
ent clinical subtypes. The dark 
red color indicates early and the 
yellow-white later involvement. 
Areas colored with gray were 
not included in the present study
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Fig. 5  Distribution map of cellular tau pathology semiquantitative 
scores (0–3) in PSP-RS cases (n = 81). White box indicates score 
0, yellow score 1, orange score 2, and red score 3 for semiquantita-
tive scoring. Presence of Lewy-body pathology above Braak stage 2 
or TDP-43 proteinopathy is indicated + , absence by −. Black boxes 
indicate that that anatomical region was not examined. On the right 
the proposed stages are indicated. Blue outlined boxes highlight the 
anatomical regions which were considered for the staging. OC Occip-
ital, TE temporal, PA parietal, FR frontal, MC motor cortex, AM 
amygdala, HI hippocampus, ST striatum, TH/STN thalamus and sub-
thalamic nucleus, GP globus pallidus, TG midbrain tegmentum, SN 
substantia nigra, LC locus coeruleus, PB pontine base, MO medulla 
oblongata, DE/Cbll dentate nucleus and cerebellar white matter
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not seen in a specific lower step of the sequential distribu-
tion in anatomical areas where accumulation is provided 
for a higher stage. Based on these concepts six sequential 
steps of tau accumulation can be recognized (Fig. 7). This 
is translated to six stages for practical neuropathological 
diagnosis:
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Step 1 of the sequence is characterized by the appearance of 
neuronal tau pathology in the globus pallidus, subthalamic 
nucleus, and substantia nigra. This vulnerability pattern 
has been already emphasized in the preliminary diagnos-
tic criteria in 1994 [13] and by Williams et al. [48], who 
added that sparse tau pathology might be seen in the motor 
cortex as well. In this stage oligodendroglial coiled bodies 
can be observed in the globus pallidus and some degree of 
astroglial tau accumulation in astrocytes in the striatum. The 
locus coeruleus and hippocampus may also show neuronal 
tau pathology; however, this is most likely influenced by 
other pathogenic processes also and reflects concomitant 
AD or PART. Further studies should specify their exact 
contribution.
Step 2 is characterized by accumulation of neuronal tau 
pathology in the midbrain tegmentum, medulla oblongata 
and pontine base, and astroglial tau pathology in the stria-
tum. A few tau positive neurons may be seen in the striatum 
but this is less than the astroglial tau pathology in the stria-
tum; thus the latter is a more consistent feature of this step. 
Oligodendroglial tau pathology further accumulates in the 
globus pallidus.
Step 3 is characterized by the accumulation of neuronal tau 
pathology in the striatum, the dentate nucleus, and the amyg-
dala, the latter influenced by concomitant AGD pathology. 
Neocortical areas (motor and frontal cortices, together rep-
resenting frontal lobe) and subthalamic nucleus and thalamic 
nuclei show increased astroglial and oligodendroglial tau 
pathology.
Step 4 is characterized by increased neuronal tau pathol-
ogy in the frontal lobe; astroglial tau accumulates in the 
amygdala, parietal, and temporal lobe. Oligodendroglial tau 
accumulates in the striatum and cerebellar white matter.
Step 5 is characterized by accumulation of neuronal tau 
pathology in the parietal and temporal lobes (involvement 
of this region is influenced also by concomitant AD/PART 
pathology). Astroglial tau increases in the occipital cortex 
and midbrain tegmentum, together with the accumulation of 
oligodendroglial tau pathology in frontal and parietal lobes 
and the brainstem (pons base, medulla oblongata, midbrain), 
as well as in the hippocampus.
Step 6 is characterized by the rare situation that neuronal 
tau increases in the occipital cortex, as well as astroglial tau 
pathology accumulates, but never reaches severe degree, in 
the substantia nigra, globus pallidus, locus coeruleus, and 
medulla oblongata. Oligodendroglial coiled bodies may fur-
ther accumulate in the occipital and temporal lobe.
For the practicing neuropathologists a simplified 
approach for the staging is summarized in Fig. 8. Single 
cellular tau immunoreactivity, defined arbitrarily as one tau 
immunoreactive cell in 20 high-power fields (× 40 objective) 
is not enough to define a stage. Although this study cannot 
exclude that tau pathology begins in the substantia nigra or 
the locus coeruleus, these regions might show single tau 
positive neurons in aging or concomitant AD/PART and, 
therefore, not included in the staging system. Apart from 
these aspects, a specific stage can be recognized if mild 
degree of tau pathology is seen.
To diagnose stage 1 detection (mild/moderate degree) of 
neuronal tau pathology in the subthalamic nucleus and neu-
ronal and/or oligodendroglial tau pathology in the globus 
pallidus and/or astroglial tau pathology in the striatum is 
required. Stage 2 is characterized by prominent tau pathol-
ogy in these regions with single cellular tau pathologies 
in the frontal cortex and/or dentate nucleus/cerebellum. 
Stages 3 and 4 can be diagnosed if astroglial tau pathol-
ogy accumulates in the frontal cortex and/or neuronal tau 
in the dentate nucleus and/or oligodendroglial tau pathol-
ogy in the cerebellar white matter. Due to interindividual 
variability (i.e., rostral or caudal predominant progression), 
the dentate nucleus and cerebellar white matter might be 
discrepant from the frontal cortex and this can be indicated 
as rostral (i.e. cortical) or caudal (i.e. dentate/cerebellar) pre-
dominant. The difference between stages 3 and 4 is based 
on the amount of tau pathologies in these regions: either 
in the frontal cortex or in dentate nucleus/cerebellum or in 
both, tau pathology has to reach moderate or severe degree 
to allow recognition of stage 4. Single tau-positive astrocytes 
may be noticed in the occipital cortex. Stages 5 and 6 can 
be recognized if astroglial tau pathology accumulates (first 
mild then to moderate/severe degree) in the occipital cortex. 
This will less likely be seen in caudal predominant forms but 
will parallel increased amount of tau pathology in all other 
regions, however, with interindividual variability (Fig. 5).
The rationale to include occipital lobe in the staging is 
that when it is involved subcortical areas are so heavily 
affected that they cannot be evaluated to distinguish further 
Fig. 6  Summary of the conditional probability analyses (see online 
supplemental file). The upper image represents whether the anatomi-
cal regions listed in the left show high, substantial, or moderate prob-
ability with a p significance value below 0.01 to precede the involve-
ment of the anatomical regions listed on the top. The lower image 
represents whether the anatomical regions listed in the left show high, 
substantial, or moderate probability with a p significance value below 
0.05 or fair probability (with p < 0.01) to precede the involvement of 
the anatomical regions listed on the top.: N neuronal, A astroglial, O 
oligodendroglial,  OC Occipital, TE temporal, PA parietal, FR frontal, 
MC motor cortex, AM amygdala, HI hippocampus, ST striatum, TH 
thalamus and subthalamic nucleus, GP globus pallidus, TG midbrain 
tegmentum, SN substantia nigra, LC locus coeruleus, PB pontine 
base, MO medulla oblongata, DE/CB dentate nucleus and cerebellar 
white matter
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Fig. 7  Sequences of PSP related tau pathology based on the condi-
tional probability matrix and stratified for accumulation of neuronal, 
astroglial, and oligodendroglial tau pathologies. Note that frontal lobe 
includes frontal and motor cortices. Note that neuronal tau pathology 
is frequently seen in the hippocampus and locus coeruleus in stage 1; 
however, eventually this may be related to concomitant Alzheimer’s 
disease or primary age-related tauopathy (PART) pathogenesis. To 
indicate that locus coeruleus is frequently affected early, but alone 
might be associated with other disease conditions such as AD/PART, 
we used italic letters
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Fig. 8  Proposed staging schema for the neuropathologi-
cal practice. −/ +  Indicates single cell involvement; + indicates 
mild; +  + / +  +  + indicates moderate/severe involvement. GP globus 
pallidus, STN subthalamic nucleus, STR striatum, FR frontal, DE/CB 
dentate nucleus and cerebellar white matter, OC occipital. This can 
be applied to all clinical subtypes. The evaluator should focus on dif-
ferent cell types in different brain regions: in GP and DE/CB neuronal 
(N) or oligodendroglial (O); in the STN neuronal; in the STR and 
FR and OC cortices astroglial (A). The brain schema is a conceptual 
summary of the tabularized schema in the lower panel; thus the color 
coding of different brain regions reflect the variability in scores (or-
or) required for a stage
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stages. Although FDG-Positron Emission Tomography 
(PET) studies on PSP do not show significant hypometabo-
lism in the occipital lobe [46], it must be noted that we also 
observe only relatively mild tau pathology. Furthermore, in 
this neuropathology staging system we focus on astroglial 
tau pathology, which might not associate with significant 
hypometabolism detectable by FDG-PET. Future studies 
using tau PET imaging are required to see whether this astro-
glial tau pathology is detectable in tau-imaging. Indeed, a 
study showing small amount of microscopically detectable 
tau pathology did not detect alterations in FDG-PET or tau-
imaging in the occipital lobe [42]. Supporting our observa-
tions, current tau-imaging studies show that the subcortical 
areas are the primary affected regions in different clinical 
subtypes [40]; however, current tau-imaging may show off 
target binding and they have not been performed in end-stage 
PSP cases.
This staging requires five blocks to be stained for phos-
pho-tau: (1) a block containing the globus pallidus and 
putamen, (2) the subthalamic nucleus, (3) frontal cortex, 
(4) cerebellum with dentate nucleus, and (5) occipital cortex. 
This staging system overlaps with the scoring strategy devel-
oped by Williams et al. [48], by emphasizing the central 
involvement of the pallido–nigro–luysian axis, basal gan-
glia, and dentate nucleus. However, contrasting that study, 
which focuses only on the accumulation of oligodendroglial 
coiled bodies and threads, we included astroglial tau pathol-
ogy in our staging and define cortical areas also as impor-
tant regions. Finally, we attempted to stage cases of various 
PSP clinical subtypes and acknowledged the practicality of 
this staging (online supplemental file Fig. 9). We noted that 
occasionally the parietal cortex might show more astroglial 
tau and can be additionally examined to diagnose stage 3. 
The overall aim of this staging is to be able to recognize 
early stages without or with only mild degree of clinical 
symptoms and these cases then can be evaluated as early or 
preclinical forms to understand earliest pathogenic events. 
Distinguishing frontal versus dentate/cerebellum predomi-
nant stages acknowledges different dynamics of propagation 
in various clinical subtypes.
Limitations of the study
First, since we examined cases with obvious clinical symp-
toms and showing considerable tau pathology, our analysis 
is not able to predict precisely where exactly neuronal tau 
pathology begins in the brainstem or subcortical nuclei. 
Second, this model is based on the accumulation and not 
the presence of a single tau cytopathology; thus the dif-
ference between regions includes no/mild pathology com-
pared to moderate/severe. Accordingly, the exact thresh-
olds might need further validation. Third, the number of 
cases in less frequent clinical subtypes did not allow the 
application of a conditional probability matrix approach 
for each subtype. However, due to the common early vul-
nerability patterns as seen in the heatmaps, we evaluated 
the staging described for PSP-RS in other clinical subtypes 
and found that the cases can confidently be included in 
these stages. Fourth, we used a semiquantitative approach 
to evaluate tau pathology, which might not be able to 
distinguish differences within cases of the same scores. 
However, since image analysis methods are not yet able 
to distinguish tau cytopathologies and provide data only 
for total tau load, we used this strategy to assess cell-spe-
cific differences. Finally, tract-specific evaluation of white 
matter pathology was not specifically addressed since we 
were interested in distribution patterns in major anatomi-
cal regions, which are evaluated in the neuropathologi-
cal practice, and according to this study, reflects well the 
progression in all clinical subtypes. However, this aspect 
can be evaluated in further studies to fine-tune subregional 
distribution patterns, which might better reflect interindi-
vidual variability.
Conclusions
Our study supports the notion that the initiating site of neu-
ronal degeneration and tau pathology seems to be similar 
in clinical subtypes, but the dynamics and propagation pat-
terns distinguish them. While neuronal tau accumulation is 
central in the pathogenesis, astroglial, and oligodendroglial 
tau accumulation is important and may precede neuronal 
tau pathology in the striatum, cortical regions, globus pal-
lidus, and cerebellar white matter (versus dentate nucleus). 
Finally, we propose a sequence of tau pathology in PSP-
RS, which allows the recognition of a pattern of pathol-
ogy and application of staging system. It seems that this 
might be applicable to various PSP subtypes; however, 
future studies should confirm this. This staging is recom-
mended for the neuropathology practice using the blocks 
usually sampled in the diagnostic practice. This will allow 
standardized comparison of cases and recognition of early-
stage cases in autopsy cohorts and in comparative studies 
with neuroimaging. However, future studies are needed to 
discover the basis of interindividual variability by evaluat-
ing further brain regions using other approaches, such as 
image analysis. Different clinical subtypes show different 
patterns of cellular tau pathologies; however, the regions 
included in the staging system parallel the accumulation 
of tau in strategic regions affected in all subtypes. Inclu-
sion of the dentate nucleus/cerebellum and frontal cortex 
for staging can help to distinguish those subtypes, which 
involve more cortical region (“rostral predominant”) from 
those which predominate in brainstem and subcortical areas 
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(“caudal predominant”). Since hypometabolism detected by 
FDG-PET correlates more with neuronal loss and not the 
accumulation of glial tau pathologies, difference in hypo-
metabolism pattern might reflect better the clinical correlate 
for subtypes. Tau-based neuroimaging will help to clarify 
whether all tau cytopathologies are detectable and can help 
to distinguish clinical subtypes. Defining cell-specific stages 
of tau pathology helps to identify preclinical cases for the 
better understanding of early pathogenic events, has implica-
tions for understanding the clinical subtype-specific dynam-
ics of disease-propagation, and informs tau-neuroimaging on 
distribution patterns.
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